JPMorgan Chase Financial Company LLC filed a free writing prospectus on October 30, 2026, disclosing terms of its 2-year non-callable for 6 months Auto Callable Contingent Interest Notes linked to the common shares of Abbott Laboratories, with a maturity date of November 2, 2028.

Key Highlights

  • Reference Stock: The notes are linked to the common shares of Abbott Laboratories.
  • Contingent Interest Rate: At least 10.25% per annum, payable quarterly at a rate of at least 2.5625% per quarter, if applicable.
  • Interest Barrier / Trigger Value: Set at 70.00% of the Initial Value, below which principal protection ceases at maturity.
  • Estimated Value: The estimated value of the notes, when terms are set, will not be less than $950.00 per $1,000 principal amount note.
  • Pricing Date / Maturity: Pricing Date is October 30, 2026; Maturity Date is November 2, 2028, with quarterly Review Dates.
  • Principal Risk: According to the filing, if the Final Value is less than the Trigger Value, investors "will lose more than 30.00% of your principal amount at maturity and could lose all of your principal amount at maturity."
  • CUSIP: 46661QWB7, issued under Registration Statement Nos. 333-293684 and 333-293684-01.

Terms and Structure of the Abbott Laboratories-Linked Contingent Interest Notes

According to the filing, JPMorgan Chase Financial Company LLC is the issuer and JPMorgan Chase & Co. serves as guarantor of the notes. The notes carry a minimum denomination of $1,000 and are structured with quarterly Review Dates over a two-year term beginning October 30, 2026. The filing states that any payment on the notes is subject to the credit risk of both the issuer and the guarantor.

The filing describes an automatic call feature: if the closing price of one share of Abbott Laboratories on any Review Date other than the first and final Review Dates is greater than or equal to the Initial Value, the notes will be automatically called. In that event, investors would receive $1,000 plus the applicable Contingent Interest Payment plus any previously unpaid Contingent Interest Payments. The filing notes that "no further payments will be made on the notes" after an automatic call.

If the notes are not called and the Final Value at the final Review Date is below the Trigger Value of 70.00% of the Initial Value, the filing discloses that the payment at maturity per $1,000 principal amount note is calculated as: "$1,000 + ($1,000 x Stock Return)." A hypothetical payment table included in the filing shows, for example, a payment of $699.900 at a stock return of -30.01%, declining to $0.000 at a stock return of -100.00%. The filing also states that the estimated value of the notes "will be lower than the original issue price (price to public) of the notes" and that J.P. Morgan Securities LLC intends, but is not required, to offer to purchase the notes in the secondary market.

What Was Disclosed

JPMorgan Chase Financial Company LLC filed a free writing prospectus disclosing the full term sheet for its 2-year Auto Callable Contingent Interest Notes linked to Abbott Laboratories common shares, including interest terms, call mechanics, principal risk scenarios, estimated value, and selected risk factors.